Citation Report

List of articles citing

Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System

#	Paper	IF	Citations
20	Midbrain atrophy in patients with presymptomatic progressive supranuclear palsy-Richardson s syndrome. *Parkinsonism and Related Disorders*, **2019**, 66, 80-86	3.6	3
19	Connectomics and molecular imaging in neurodegeneration. *European Journal of Nuclear Medicine and Molecular Imaging*, **2019**, 46, 2819-2830	8.8	7
18	[Recommendation for the differentiated use of nuclear medical diagnostic for parkinsonian syndromes]. *Fortschritte Der Neurologie Psychiatrie*, **2020**, 88, 609-619	0.5	0
17	Towards accurate and unbiased imaging-based differentiation of Parkinson s disease, progressive supranuclear palsy and corticobasal syndrome. *Brain Communications*, **2020**, 2, fcaa051	4.5	7
16	Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy. *JAMA Neurology*, **2020**, 77, 1408-1419	17.2	54
15	Various Diseases and Clinical Heterogeneity Are Associated With "Hot Cross Bun". *Frontiers in Aging Neuroscience*, **2020**, 12, 592212	5.3	9
14	Central autonomic dysfunction in multiple system atrophy: can we measure it with MRI?. *Clinical Autonomic Research*, **2020**, 30, 185-187	4.3	
13	Magnetic Resonance Imaging Biomarkers Distinguish Normal Pressure Hydrocephalus From Progressive Supranuclear Palsy. *Movement Disorders*, **2020**, 35, 1406-1415	7	22
12	Novel decision algorithm to discriminate parkinsonism with combined blood and imaging biomarkers. *Parkinsonism and Related Disorders*, **2020**, 77, 57-63	3.6	9
11	Automated MRI Classification in Progressive Supranuclear Palsy: A Large International Cohort Study. *Movement Disorders*, **2020**, 35, 976-983	7	20
10	A New MRI Measure to Early Differentiate Progressive Supranuclear Palsy From De Novo Parkinson s Disease in Clinical Practice: An International Study. *Movement Disorders*, **2021**, 36, 681-689	7	11
9	Contributions of PET and MRI imaging in the evaluation of CNS drugs in human neurodegenerative diseases. *Therapie*, **2021**, 76, 121-126	3.8	
8	Cortical [F]PI-2620 Binding Differentiates Corticobasal Syndrome Subtypes. *Movement Disorders*, **2021**, 36, 2104-2115	7	6
7	Feasibility of short imaging protocols for [F]PI-2620 tau-PET in progressive supranuclear palsy. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 3872-3885	8.8	1
6	Dual-Phase FAmyloid PET Captures Neuronal Injury and Amyloidosis in Corticobasal Syndrome. *Frontiers in Aging Neuroscience*, **2021**, 13, 661284	5.3	1
5	Validation of biomarkers in Huntington disease to support the development of disease-modifying therapies: A systematic review and critical appraisal scheme. *Parkinsonism and Related Disorders*, **2021**, 93, 89-96	3.6	0
4	A data-driven model of brain volume changes in progressive supranuclear palsy. *Brain Communications*,	4.5	1

3   Table_1.DOC. **2020**,

2   Additive value of [18F]PI-2620 perfusion imaging in progressive supranuclear palsy and corticobasal syndrome.   0

1   Symptomatology in 4-repeat tauopathies is associated with data-driven topology of [18F]-PI-2620 tau-PET signal. **2023**, 38, 103402   0

2   Additive value of [18F]PI-2620 perfusion imaging in progressive supranuclear palsy and corticobasal